DK3107906T3 - Reduceret central hornhindefortykkelse under anvendelse af hydrofile ester-prodrugs af beta-chlorcyclopentaner - Google Patents

Reduceret central hornhindefortykkelse under anvendelse af hydrofile ester-prodrugs af beta-chlorcyclopentaner Download PDF

Info

Publication number
DK3107906T3
DK3107906T3 DK15759564.6T DK15759564T DK3107906T3 DK 3107906 T3 DK3107906 T3 DK 3107906T3 DK 15759564 T DK15759564 T DK 15759564T DK 3107906 T3 DK3107906 T3 DK 3107906T3
Authority
DK
Denmark
Prior art keywords
compound
pharmaceutical composition
mmol
etoac
glaucoma
Prior art date
Application number
DK15759564.6T
Other languages
English (en)
Inventor
Robert M Burk
Wha Bin Im
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/185,556 external-priority patent/US9090595B2/en
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK3107906T3 publication Critical patent/DK3107906T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (5)

1. Forbindelse valgt fra gruppen bestående af:
2. Farmaceutisk sammensætning omfattende forbindelsen ifølge krav 1 og en farmaceutisk acceptabel bærer.
3. Forbindelse ifølge krav 1 eller den farmaceutiske sammensætning ifølge krav 2 til anvendelse som medikament.
4. Forbindelse ifølge krav 1 eller den farmaceutiske sammensætning ifølge krav 2 til anvendelse i en fremgangsmåde til behandling afen øjensygdom hos et menneske, hvor fremgangsmåden omfatter indgivelse af en terapeutisk effektiv mængde af forbindelsen eller den farmaceutiske sammensætning til et individ, der har behov derfor.
5. Forbindelse ifølge krav 1 eller den farmaceutiske sammensætning ifølge krav 2 til anvendelse i en fremgangsmåde til reduktion af hornhindefortykkelse, hvor fremgangsmåden omfatter indgivlese afen terapeutisk effektiv mængde af forbindelsen eller den farmaceutiske sammensætning til et individ, der har behov derfor.
DK15759564.6T 2014-02-20 2015-02-19 Reduceret central hornhindefortykkelse under anvendelse af hydrofile ester-prodrugs af beta-chlorcyclopentaner DK3107906T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/185,556 US9090595B2 (en) 2012-08-27 2014-02-20 Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
PCT/US2015/016660 WO2015175075A1 (en) 2014-02-20 2015-02-19 Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

Publications (1)

Publication Number Publication Date
DK3107906T3 true DK3107906T3 (da) 2019-03-18

Family

ID=54062793

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15759564.6T DK3107906T3 (da) 2014-02-20 2015-02-19 Reduceret central hornhindefortykkelse under anvendelse af hydrofile ester-prodrugs af beta-chlorcyclopentaner

Country Status (10)

Country Link
EP (1) EP3107906B1 (da)
JP (1) JP6626831B2 (da)
KR (1) KR20160124835A (da)
CN (1) CN106029643A (da)
AU (1) AU2015259752B2 (da)
CA (1) CA2939569A1 (da)
DK (1) DK3107906T3 (da)
ES (1) ES2717481T3 (da)
TR (1) TR201902864T4 (da)
WO (1) WO2015175075A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015327817B2 (en) 2014-10-02 2020-04-23 Allergan, Inc. Ester prodrugs of gamma-lactams and their use
JP7197880B2 (ja) * 2017-10-19 2022-12-28 学校法人 名城大学 エステル化剤及びその利用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO2008008718A2 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Cyclopentane derivatives as antiglaucoma agents
US20080015219A1 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Therapeutic compounds
US7947732B2 (en) * 2007-07-13 2011-05-24 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
US7732443B2 (en) * 2008-03-18 2010-06-08 Yariv Donde Therapeutic substituted cyclopentanes
US7960378B2 (en) * 2008-03-18 2011-06-14 Allergan, Inc. Therapeutic compounds
US7737140B2 (en) * 2008-04-24 2010-06-15 Allergan, Inc. Therapeutic compounds
RU2567792C2 (ru) 2009-11-09 2015-11-10 Аллерган, Инк. Композиции и способы стимулирования роста волос
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
WO2014035827A1 (en) * 2012-08-27 2014-03-06 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

Also Published As

Publication number Publication date
JP2017509610A (ja) 2017-04-06
AU2015259752A1 (en) 2016-09-01
CN106029643A (zh) 2016-10-12
WO2015175075A1 (en) 2015-11-19
AU2015259752B2 (en) 2019-06-20
ES2717481T3 (es) 2019-06-21
JP6626831B2 (ja) 2019-12-25
KR20160124835A (ko) 2016-10-28
CA2939569A1 (en) 2015-11-19
TR201902864T4 (tr) 2019-03-21
EP3107906A1 (en) 2016-12-28
EP3107906B1 (en) 2018-12-05

Similar Documents

Publication Publication Date Title
DK2888239T3 (da) Reduceret central hornhindefortykkelse ved anvendelse af hydrofile esterprodrugs af beta-chlorcyclopentaner
JP2023030072A (ja) 併用療法
JP2010510232A (ja) 眼圧降下剤であるプロスタグランジンプロドラッグ
KR20100131976A (ko) 고 안압증의 치료를 위한 디플루오로바이페닐아미드 유도체
DK3107906T3 (da) Reduceret central hornhindefortykkelse under anvendelse af hydrofile ester-prodrugs af beta-chlorcyclopentaner
US9090595B2 (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
ES2733756T3 (es) Agentes terapéuticos para el tratamiento de hipertensión ocular
EP3201192B1 (en) Ester prodrugs of gamma-lactams and their use
JP2014524935A (ja) Ｎ，ｎ−ジアルキルアルキレニルエステル類、その組成物およびその使用方法